Photo by nci from unsplash
tively. The cumulative incidences of relapse (RI) were 23.5% and 21.5% (P = .482), and those of NRM were 20.0 % and 28.2% (P = .44), respectively. And cumulative incidences… Click to show full abstract
tively. The cumulative incidences of relapse (RI) were 23.5% and 21.5% (P = .482), and those of NRM were 20.0 % and 28.2% (P = .44), respectively. And cumulative incidences of chronic GVHD were 42.3% and 39.6%(P=0.46), respectively. These data showed no difference in every major HSCT endpoint between two groups. Multivariate analysis suggested that occurrence of grade III-IV aGVHD had a significant worse outcome, primary chemorefractory was the strongest factors for relapse. Conclusion: Our results indicate that the outcomes of haplo-SCT are equivalent to HLA-matched SCT, and that MAC followed by haploSCT can be an acceptable and feasible alternative for patients with R/R NHL who having no access to a HLA-matched donor.
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!